Shares of Arrowhead Pharmaceuticals, Inc. (ARWR) are gaining over 16% on Tuesday morning after the company announced interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE, the company’s investigational RNA interference therapeutic designed to reduce the production of the receptor for advanced glycation end products as a potential treatment for inflammatory pulmonary diseases, such as asthma.
ARWR is currently trading at $35.10, up $5.08 or 16.94%, on the Nasdaq. The stock opened its trading at $35.02 after closing Monday’s trading at $30.02. The stock has traded between $23.09 and $48.48 in the past 52-week period.
The company said the data represent the first clinical demonstration of the potential utility of Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform optimized for delivery to the lungs.
Matthias Salathe, M.D., Professor, Pulmonary, Critical Care and Sleep Medicine, and Vice Chancellor for Research at the University of Kansas Medical Center, said: “These interim ARO-RAGE Phase 1/2 data are highly encouraging. Unmet need continues to exist for many patients with severe asthma who suffer from persistent symptoms and exacerbations, despite current therapies. Reducing expression of the RAGE protein in pulmonary epithelial cells to the degree that ARO-RAGE has demonstrated to date in this study has the potential to treat patients with asthma and other inflammatory lung diseases in a fundamentally new way. RAGE represents a promising target for intervention as its activation has been implicated as a proximal regulator of the inflammatory cascade in the asthmatic airway, and thus RAGE silencing may result in potent anti-inflammatory effects. I look forward to the availability of additional results from this important trial.”
Source: Read Full Article